Seropositive rheumatoid arthritis (RA), which occurs in individuals who have both genetic and familial risk factors for this disease [1] [2] [3] [4] , begins with a prolonged period (several years) of serologically detectable RA-related autoimmunity associated with the presence of systemic inflammatory biomarkers but the absence of clinical or histologically defined inflammatory arthritis [5] [6] [7] [8] [9] . Serum autoantibodies present at this time include multiple isotypes of both anti-citrullinated protein antibodies (ACPAs) and Fc domain-recognizing rheumatoid factors (RFs) in patterns highly predictive of the future onset of joint disease 5, 6, 9, 10 . This period can be defined retrospectively as the 'preclinical' period of RA in patients who eventually develop the disease 11 , and as an 'at-risk' period for individuals who are seropositive and/or have familial or clinical risk factors but have not yet developed arthritis when studied in a crosssectional or longitudinal manner. This preclinical condition is followed by the development of early clinically detectable inflammatory arthritis and/or classified RA, the latter of which proceeds as a chronic arthritis and disease process that can also involve the lung and other target organs.
Data from epidemiological and translational studies suggest that mucosal environmental exposures and/or dysbiosis have causal roles during the at-risk period in the development of RA 2, [12] [13] [14] [15] [16] . However, despite support for a 'mucosal origins hypothesis'-that is, that RA development begins at mucosal sites and then transitions to involve the synovial joints -these studies are limited in that they do not enable identification of the specific mucosal processes present at the initial time point or points during which such exposures would have influenced the concurrent autoimmune phenotypes as well as subsequent disease evolution and arthritis development. In this regard, it is often assumed that a key factor in early RA development is the loss of self-tolerance to citrullinated self-antigens. However, studies of at-risk individuals as well as healthy individuals strongly suggest that mucosal, and probably systemic, immunoglobulin A (IgA) isotype ACPA and RF generation is a common finding and is associated with local mucosal Abstract | Individuals at high risk of developing seropositive rheumatoid arthritis (RA) can be identified for translational research and disease prevention studies through the presence of highly informative and predictive patterns of RA-related autoantibodies, especially anti-citrullinated protein antibodies (ACPAs), in the serum. In serologically positive individuals without arthritis, designated ACPA positive at risk , the presence of mucosal inflammatory processes associated with the presence of local ACPA production has been demonstrated. In other at-risk populations, local RA-related autoantibody production is present even in the absence of serum autoantibodies. Additionally , a proportion of at-risk individuals exhibit local mucosal ACPA production in the lung, as well as radiographic small-airway disease, sputum hypercellularity and increased neutrophil extracellular trap formation. Other mucosal sites in at-risk individuals also exhibit autoantibody production, inflammation and/or evidence of dysbiosis. As the proportion of individuals who exhibit such localized inflammation-associated ACPA production is substantially higher than the likelihood of an individual developing future RA , this finding raises the hypothesis that mucosal ACPAs have biologically relevant protective roles. Identifying the mechanisms that drive both the generation and loss of externally focused mucosal ACPA production and promote systemic autoantibody expression and ultimately arthritis development should provide insights into new therapeutic approaches to prevent RA.
inflammation 17, 18 . These findings suggest that the most important early event in the preclinical development of RA is not loss of tolerance to self-antigens but instead loss of the mucosal barrier function and systemic spread of an IgG ACPA response. With those issues in mind and to address the mucosal origins hypothesis in the context of findings in individuals at risk of developing RA in the future, this Review describes the available evidence linking the presence of RA-related autoimmunity in specific at-risk populations with the concurrent presence of local mucosal inflammation and autoantibody production, mucosal dysbiosis and/or systemic immune dysregulation consistent with mucosal inflammation.
Development of seropositive RA
RA is an autoimmune disease that evolves over decades and manifests as both locally joint-destructive and systemic illness 4, 19 . The disease is characterized by widespread inflammation as well as local joint-based signs and symptoms ranging from arthralgias, a term that has been specifically defined for research purposes to encompass seven factors (symptom duration <1 year, symptoms of metacarpophalangeal (MCP) joints, morning stiffness duration ≥ 60 minutes, most severe symptoms in early morning, first-degree relative (FDR) with RA, difficulty with making a fist and a positive squeeze test of MCP joints) 20 , to swelling, pain and inflammatory synovitis that are clinically detectable through techniques such as physical examination, imaging and synovial biopsy (reviewed elsewhere 19, 21 ). Osteopenia and local erosions commonly occur in RA, probably through inflammatory and remodelling processes that alter relative rates of bone formation and degradation by osteoblasts and osteoclasts, respectively 22 . RA exhibits a prevalence of 0.5-0.8% in the general population, and an ~3-5-fold increase in FDRs (reviewed elsewhere 23 ), which seems to be owing to both genetic and environmental influences [24] [25] [26] . Patients receive a diagnosis of RA according to the 1987 revised ACR or 2010 ACR/EULAR classification criteria 27, 28 . In some patients, RA first appears clinically as an undifferentiated inflammatory arthritis 29, 30 .
The term 'RA' encompasses two major subsets of disease, seropositive and seronegative, that exhibit overlapping but individually distinct pathogenic mechanisms and clinical courses (reviewed elsewhere 21, 26, 31 ). Seropositive individuals exhibit substantial overlap of expression of two primary autoantibody systems: ACPAs, which are antibodies towards a posttranslational modification (citrullination) that is found in an antigenic form on fibrinogen, vimentin, type II collagen (CII), histones and enolase 32, 33 , and antibodies to the Fc domains of self-immunoglobulin molecules, designated RFs 34 . Additional anti-modified protein antibodies (AMPAs) (reviewed elsewhere 35 ), such as anti-carbamylated protein antibodies 36 and antibodies to malondialdehyde-acetaldehyde-modified epitopes 37 , have been identified in patients with RA. However, the specificity of these AMPAs for RA, and at what point in the transition from preclinical to clinically apparent disease AMPAs develop, are less well defined 38, 39 . RA can be driven by a variety of genetic and environmental factors that lead to a heterogeneous disease process with variable autoantibody positivity. In terms of genetic factors, many genes are associated with RA, including high-risk HLA-DR alleles containing the shared epitope (SE) 40 and PTPN22 (ref. 41 ), as well as many other genes with low relative risk variants 42 . Systemic targeting of citrullinated proteins is probably facilitated by the preferential interactions of peptides bearing citrulline with SE-containing HLA-DR molecules [43] [44] [45] . Heterogeneity in RA disease phenotypes is also likely to be influenced by environmental factors 25, 46 . In addition, epigenetic changes associated with RA affect lymphocytes, fibroblast-like synoviocytes and other cell populations 3, 4, 47, 48 .
In patients who eventually develop seropositive RA, there is a prolonged asymptomatic preclinical period without evidence of joint involvement that is characterized by the presence of serologically detectable ACPAs, measured through clinical tests for anti-CCP (cyclic citrullinated peptide) antibodies, and RFs; this evolving process typically occurs 3-5 years prior to the onset of clinically apparent and classified disease (reviewed elsewhere 49 ) ( fig. 1 ). Shortly before the onset of clinically apparent arthritis, systemic levels of cytokines and chemokines increase in a heterogeneous manner, with regard to both the number and the pattern of individual mediators that are increased in an individual patient 10 . An increase in epitope spreading also occurs, encompassing a wide variety of citrullinated targets 9, 50 ; avidity maturation of autoantibodies is also present 51 . In addition, effector functions of ACPAs evolve during the development of RA 51, 52 . For example, altered ACPA Fc domain galactosylation and fucosylation 53 , as well as excessive Fab (antigen-binding fragment) glycosylation 54 , are common findings in patients with RA and in patients who are transitioning from the arthralgia state to inflammatory arthritis and classified RA; these processes probably have important roles in autoantibody selection and/or pathogenicity. Notably, studies have suggested that IL-23 and T helper 17 (T H 17) cells regulate the β-galactoside α2,6-sialyltransferase 1 activity in B cells that controls the extent of glycosylation
Key points
• Patients who eventually develop seropositive rheumatoid arthritis (RA) pass through a period of RA-related autoantibody positivity that is associated with increased levels of cytokines and chemokines.
• Various mucosal processes can influence the development of systemic immunity and autoimmunity.
• Individuals who are at high risk of the future development of RA demonstrate evidence of chronic systemic and mucosal inflammation.
• Rather than reflecting a loss of citrullinated antigen tolerance, immunoglobulin A (IgA) anti-citrullinated protein antibodies (ACPAs) are normally produced locally; a systemic IgG response likely results from loss of externally focused compartmentalization.
• Ongoing studies are linking the development of mucosal dysbiosis, inflammation and autoantibody production to the next stages of development of systemic autoimmunity.
• Novel autoimmune-promoting processes are likely to be identified that function primarily, or exclusively, in the preclinical period of RA and could be the targets for new prevention strategies.
Shared epitope
A set of HLA antigens that are preferentially found in patients with rA and that are characterized by conserved amino acids within the peptide-binding groove.
Epitope spreading
A process in which the epitopes (target antigen shapes or sequences recognized by B and T cell receptors) that are distinct from and non-cross-reactive with the initial target epitope become major targets of an ongoing immune response.
Avidity maturation
A process in which the accumulated strength of multiple affinities of individual non-covalent binding interactions between antigens and antibodies increases over time.
NATuRE REviEwS | RhEumAtoLogy of immunoglobulin molecules and their pathogenic potential and that changes in these cytokines drive the disease-enhancing changes in secreted autoantibodies during the clinical transition to arthritis 55 . Importantly, autoantibodies that demonstrate effector functions related to osteoclastogenesis 56 and joint pain secondary to chemokine release 57 have also been identified in patients with RA, although the point during disease development at which these autoantibodies appear is less certain. Perhaps most intriguingly relative to mucosal studies, IgA ACPA and RF isotypes long precede the development of classified RA 58 , although the relative timing of the appearance of each serum RA-related autoantibody isotype is not yet clearly defined. In addition, in patients with RA, RF contains a high proportion of secretory component, which is necessary to transport IgA across the mucosal surface 59 , although the time point of appearance of this feature is again uncertain.
Identifying early immune alterations
Studies in the preclinical time period have primarily relied on two experimental approaches. The first approach has been to utilize annotated sera that have been collected previously for other purposes -for example, from blood banks and population studies 5, 6, 8, 60 as well as the US Department of Defense Serum Repository 7 . Despite the inherent limitations of patients not being studied and classified with regard to arthritis status at the same time as the sample acquisition, many insights have been generated from these approaches. However, another approach is to perform studies of individuals with an ACPA-positive at-risk status, which is a method that has increasingly helped to define how the earliest immunological abnormalities develop and what might be the early 'drivers' of disease. These individuals are recruited through many different means, including recruitment of FDRs, who are themselves at higher risk of developing disease 61, 62 , outreach at community health fairs or other events to identify serum ACPA-positive at-risk individuals 63 and the creation of referral networks to specifically identify patients in primary care with arthralgias suggestive of preclinical RA who are subsequently followed for development of inflammatory arthritis and classified RA 64 . Individuals who are at risk of future RA can be defined on the basis of increased risk as an FDR, which enables one to study phenotypes and epidemiological factors in real time prior to the development of serological positivity for ACPAs or RFs. Thus, within each study it is important to define the basis for increased risk in the population or populations being studied and the control population or populations against which findings are compared. Finally, ongoing population recruitment efforts include screening of biobanks and electronic health records, social media outreach and the increasing number of referrals to rheumato logists of patients without inflammatory arthritis or arthralgias who are found to be ACPA positive.
This heterogeneity in sources of samples might lead to some differences in the findings from retrospective studies. Nevertheless, a number of important observations have been made using these approaches (Box 1). Key findings in serum samples from at-risk populations include the presence of increased levels of chemokines, cytokines and inflammatory biomarkers 62, 65, 66 , altered T cell phenotypes 67, 68 and increased numbers of autoantibodies 61, 65, [69] [70] [71] . Importantly, many of these biomarker patterns mirror those found in the serum from retrospectively studied populations and strongly support the idea that these individuals are indeed in a preclinical period of RA development.
Stage-specific environmental factors
The potential roles of environmental exposures in the development of RA have been reviewed extensively 23, 25 . With regard to the at-risk population, however, very few long-term prospective studies have been performed to understand how stage-specific exposures influence the initial preclinical development of RA-related autoimmunity and subsequent clinical and/or immune transitions. Nevertheless, a number of informative crosssectional and short-term longitudinal studies have been performed in such individuals (TABLe 1) .
A well-accepted association in RA is the relationship between heavy smoking and the risk of development of seropositive RA, with the predominant risk being in patients with the SE 26 . The exact stage-specific timing of . Shown in the middle of this figure is the EUL AR recommended terminology for defining the various disease stages in the natural history of RA and those stages corresponding to patients in the preclinical stages (when defined retrospectively) or 'at risk' (when defined crosssectionally or longitudinally). Examples of the epidemiological and genetic factors, and features of systemic immune dysregulation that are under investigation are listed in boxes above; the study of these various features in the preclinical period could help to understand the causal drivers of preclinical disease. Past studies of these populations have included retrospective analysis of serum samples and biomarkers in patients in the preclinical stages of disease. ACPAs, anti-citrullinated protein antibodies; CTL A4, cytotoxic T lymphocyte protein 4; HPA , hypothalamic-pituitary-adrenal; PTPN22, protein tyrosine phosphatase non-receptor type 22; PUFAs, polyunsaturated fatty acids; RF, rheumatoid factor ; STAT4, signal transducer and activator of transcription 4; TRAF1-C5, TNF receptor-associated factor 1-complement component 5.
www.nature.com/nrrheum smoking effects is not well understood, but several studies have provided insights. For example, initial studies of at-risk individuals in a well-studied cohort evaluated in real time revealed that heavy smoking is associated with asymptomatic RF positivity 72 . In a Swedish twin study, heavy smoking imparted an increased risk of being ACPA positive without RA, and this increased risk had no major relationship to the SE in the preclinical period 73 . In addition, in a large ( > 40,000 individuals) population study in the Netherlands, a positive ACPA status was associated with smoking as well as with older age and joint symptoms 74 . Further support for a role of smoking exposure in the future development of RA was provided by a Swedish population study in which smoking was associated with an increased risk of development of both seropositive and seronegative RA 75 . Similarly, in a Japanese non-RA cohort, a history of smoking was associated with a positive RA-related autoantibody status, but interestingly only when both ACPAs and RFs were present 76 . In a further analysis of the same population, ACPAs and RFs were shown to associate with each other; smoking was associated with a higher level of ACPAs, but the presence of the SE was not associated with an ACPA-positive status, and no interaction was found between the SE, smoking and autoantibody positivity 77 . Thus, smoking seems to have an important role in the initial development of ACPAs, but does not have a clear relationship to SE status, which itself seems to have a more important role in the transition to classified RA.
With regard to other factors, a history of birth control pill use is inversely associated with RF positivity 72 . These results are consistent with findings from patients with classified RA 23, 25 and suggest that this exposure has a key early role in preclinical RA.
Conversely, particulate air pollution is not associated with RA-related autoimmunity in at-risk individuals 78 , in contrast to the positive association seen in patients with classified RA 79 , suggesting that this exposure has a later role in the development of RA, perhaps promoting the transition from RA-related autoantibodies alone to the initial synovitis. Additional results from the Nurses Health Studies have suggested that an increased BMI in conjunction with an expanded ACPA repertoire is associated with increased risk of developing RA and accelerated transition to arthritis 80 . Studies from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) have also suggested that exposure to silica increases the risk of future development of RA 81 . Associations between RA development and other occupational exposures, hormonal factors, dietary intake or alcohol use have previously varied, and the roles of these exposures in the preclinical stages of diseases are less well understood (reviewed elsewhere 25 ). An intriguing finding is the inverse relationship between the presence of RA-related autoantibodies in at-risk populations and the intake of omega-3 fatty acids as well as the presence of lipid biomarkers that measure levels of these key anti-inflammatory molecules. Notably, both established and emerging evidence demonstrates that polyunsaturated fatty acids (PUFAs) derived from the omega-3 fatty acid biosynthesis pathway might have an important role in RA treatment and prevention 82, 83 . Omega-3 PUFA supplementation in patients with classified RA has been shown to reduce signs and symptoms of inflammation and lead to decreased use of other therapeutic agents 82, 83 . Population-based approaches have demonstrated that increased intake of fish rich in omega-3 PUFAs and direct supplementation with PUFAs are associated with a reduced risk of developing RA 84 . Increased omega-3 intake as well as increased levels of the red blood cell (RBC) omega-3 fatty acid pathway products eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are associated with a decreased risk of RA-related autoantibody positivity in individuals with a genetic risk of developing RA 85 . Specifically, the likelihood of anti-CCP2 positivity in patients was inversely associated with total percentage of omega-3 PUFAs in RBCs (OR = 0.47; 95% CI 0.24-0.92, for a 1 s.d. increase); anti-CCP2-positive individuals were less likely than CCP2-negative demographically matched controls to report omega-3 supplement use (OR = 0.14; 95% CI 0.03-0.68). Intriguingly, the effect was strongest in individuals with the SE 86 . In further observational studies of ACPA-positive individuals without synovitis at baseline, lower levels of RBC omega-3 PUFAs were associated with an increased risk of progression to inflammatory arthritis 87 .
Mucosal origins hypothesis
The mucosal origins hypothesis suggests that the disease process in patients who eventually develop RA originates at one or more sites in the mucosa. The theory historically derived from an early suggestion that RA was an infectious illness. Later suggestions included the possibility that RA developed through cross-reactivity to bacterial, viral and/or mycobacterial antigens carried in organisms such as Proteus (reviewed elsewhere 88 ). Furthermore, the finding that Porphyromonas gingivalis, NATuRE REviEwS | RhEumAtoLogy a major cause of periodontitis, produces an enzyme capable of citrullinating proteins suggested another means by which mucosal dysbiosis could drive or influence disease development 89 . Nevertheless, the hypothesis remains unproven, although evidence from an increasing number of studies is consistent with a major role for the microbiome in RA development.
The microbiome and autoimmunity
Increasing evidence from both murine and human translational research studies points to the important role of the microbiome (present in the intestine and other mucosal sites as well as epithelial sites) in modulating the immune, as well as autoimmune, response (reviewed elsewhere 90 ). Food intake and other environmental exposures influence the development and maintenance of microbial kingdoms, including bacterial, fungal, helminth and viral organisms. Mucosal exposure to specific microbial antigens and the metabolic products of biosynthesis and energy generation or utilization by microbes has a major effect on the immune system 2, 91 . Studying the microbiome in humans has many challenges 90 , including lack of direct access to most mucosal sites, difficulty in isolating and expanding many species in a manner that replicates the local mucosal ecosystem, an incomplete understanding of microbial genotype-phenotype relationships, substantial changes introduced to the microbiome by food exposures such as dietary emulsifiers and noncaloric sweeteners, long-term imprinting by the fetal microbiome whose effects cannot be discerned years later, cultural differences around food and other exposures that affect microbial communities and the rapid changes that can ensue following alterations in the environment (perhaps best demonstrated by the effects of changing food intake on the microbial community in the gastrointestinal tract 90 ).
Crosstalk with the local immune system. The local mucosal immune system can interact with, respond to and constrain the microbiome in a number of ways ( fig. 2 ), including induction and inhibition mechanisms that are strongly influenced by cells of the adaptive immune system as well as distinct types of mononuclear phagocytes 90 . An important feature of the crosstalk process between the immune system and the micro biome is the mucosal barrier, which is created not only by interepi thelial cell tight junctions but also by the integrity of the mucus layer (reviewed elsewhere 92 ). Additional components of the mucosal barrier include antimicrobial peptides (encompassing the microbicidal protein RegIIIγ and related families 93 ), antibodies, macro phages, dendritic cells, regulatory T (T reg ) cells and T H 17 cells. Neutrophils are also important in mucosal defence from infection; these cells are attracted to the lumen through polarized secretion of IL-8 by epithelial cells as well as bioactive lipids, especially hepoxilin A3 (reviewed elsewhere 94 ). CD4 + and CD8 + T cells also continuously survey antigens in this region, the responses to which are regulated by cytokines, including IL-17, IL-10, IL-22, IL-23, IL-6 and TNF family members, in addition to other populations such as T reg cells. In addition, specialized mucosalassociated invariant T (MAIT) cells, the innate immune functions and activation state of which are intimately tied to MHC class I-related gene protein (MR1) ligands that are upregulated during mucosal infection and inflammation, are present and produce IL-17 and T H 1 cytokines 95 . Type 3 innate lymphoid cells contribute to the mucosal immune response through production of IL-22, a cytokine that stimulates production of RegIII lectins in response to dysbiosis 96 and controls epithelial cell fucosylation to provide a carbohydrate source utilized by certain microbial subsets 97 . Also present are mucosal homing receptor 98 and CXC-chemokine receptor 4 (CXCR4) low and that undergo antigen-specific activation in the development of mucosal inflammation 99 . With regard to antibodies, IgA is the major Ig isoform produced at most mucosal surfaces, and although circulating blood levels of this immunoglobulin are low, IgA is the most highly produced immunoglobulin isoform in the body 100 . Importantly, both T cell-dependent and T cell-independent means regulate the production of this mucosal isoform 101 . IgA exists as monomeric and polymeric forms of IgA1 and IgA2 sub-isotypes as well as polymeric IgA linked by the J chain. The IgA Fc receptor (FcαRI) is found on neutrophils, monocytes, eosinophils and a subset of dendritic cells, and IgA functions to increase the respiratory burst in immune cells and inhibit bacterial adhesion 100 . Several contrasting roles have been ascribed to the IgA isotype. Its primary role is to recognize and neutralize pathogens and exotoxins at the mucosal surface and in that way to regulate the microbiome, maintain homeostasis and protect intestinal and other barriers from pathogens. A key mechanism is to block infection and invasion of the mucosa through inhibiting transport across the epithelium and enabling clearance by peristalsis in the gut 102 . IgA plasmablasts are primarily generated in Peyer's patches and can circulate to secrete antibodies at other mucosal sites. Although IgA is viewed primarily in the context of mucosal immunity, when present systemically at high levels in immune complexes it can damage target tissues, including the joint 103 . In another sense, secreted IgA antibodies can be considered to be anti-inflammatory as they are typically not strongly complement activating and are resistant themselves to proteolytic degradation 104 . Thus, the proinflammatory versus anti-inflammatory roles of IgA must be considered to be context-dependent and probably coexisting. Beyond IgA, there are prominent roles for IgM antibodies as well as IgG antibodies and the bidirectional transport of both isotypes by the neonatal Fc receptor (FcRn) in the regulation of the microbiome and control of local pathogens, perhaps most prominently in the cervicovaginal fluid (reviewed elsewhere 105 ). Notably, bacteria that penetrate the mucosal barrier are recognized by locally produced IgA isotype antibodies that are typically polyreactive 106 ; if these bacteria avoid neutralization and elimination, they can more readily cross the epithelial layer and have antigens be presented by dendritic cells 107 . In addition to bacteria, viruses and other species can profoundly influence the mucosal immune response 90 . Examples include bacteriophages as well as DNA and RNA viruses 108 . Other organisms, including mycobacteria, fungi and helminths, can have key roles in regulating local and systemic immune responses 90 . To date, little information is known regarding the potential influence of the non-bacterial microbiome on the preclinical initiation or evolution of autoimmune diseases.
Another important feature of the mucosal immune response is the regulatory effect of the microbiome on local cells, as demonstrated by the generation of bacterial metabolites that modulate differentiation and effector functions. For example, the microorganismderived short-chain fatty acids butyrate, propionate and acetate all strongly affect the differentiation of mucosal T reg cells 109 .
Evidence of disease modulation from experimental models. Several murine models of arthritis have been studied to investigate what changes occur in the mucosal microbiome during the evolution of experimental arthritis and how these changes can affect the development of systemic autoimmunity and synovitis. Together, these studies strongly support a role for microbiome influences on arthritis development through several mechanisms.
Important pathogenic roles for the ACPA response have been demonstrated in the CII-induced arthritis (CIA) model, along with the potential benefits (in terms of clinical and autoimmune outcomes) of modulating the ACPA response using tolerogenic approaches to decrease the level of pathogenic ACPAs 110 . In one study, researchers demonstrated the presence of dysbiosis in the CIA model; furthermore, transfer of faecal material from the arthritic mice, but not from the mice that did not develop arthritis in the same experiment, accelerated the development of arthritis in recipient germ-free mice 111 . Additionally, increases in levels of IL-17 and splenic CD8 and T H 17 cells were seen with this procedure, in contrast to decreases in numbers of dendritic cells, B cells and T reg cells. Another study demonstrated that although modulation of the microbiota through the use of broad-spectrum antibiotics prior to the induction of CIA resulted in a modest reduction in disease severity, antibiotic use during the late phase of CIA resulted in nearly complete suppression of arthritis 112 . The effect of antibiotic treatment during the late phase of CIA was in part owing to substantial impairment of the ability of anti-CII antibodies to activate complement ex vivo; by contrast, the reduction in disease severity in mice treated with antibiotics prior to CIA induction was associated with decreased levels of circulating inflammatory cytokines and anti-CII antibodies along with delayed IL-17 A and IL-22 production in the intestine.
Perhaps most notably, these data establish that the microbiome can exert profoundly different effects during the preclinical to clinical evolution of arthritis, a finding that is probably quite germane to the study of the potential roles of the human microbiome during initiation of autoimmunity and through the multiple stages of the natural history of RA. In addition, the effects of mucosal immune cell interactions with the micro biome might not be limited to local effects -subsets of lympho cytes in the mucosa are also known to recirculate and populate other sites and in that process influence the immune and autoimmune response in other tissues 113 . Indeed, it might be that 'licensing' of T cells and B cells to become pathogenic must occur through either local activation or passage of these cells through mucosal sites, especially the gut but perhaps also the lung, after which they can then elaborate their pathogenic potential in target tissues during autoimmune disease processes.
Other models of RA have demonstrated features that highlight the differing roles of the microbiome in human disease. For example, the K/BxN T cell receptor (TCR) transgenic mouse is a model in which CD4 + T cell-driven autoantibody recognition of the ubiquitous autoantigen glucose-6-phosphate isomerase (GPI) results in an immune-complex-driven arthritis 114 . In a germ-free environment, transgenic mice exhibit delayed onset and reduced severity of arthritis. However, segmented filamentous bacteria are capable of modulating the development of autoantibodies to GPI by activating and recruiting T H 17 and T follicular helper cells within the intestine 115, 116 . In addition, studies of DR4 and/or DQ8 humanized mice have demonstrated that treatment with a human commensal organism, Prevotella histicola, suppressed the development of CIA 117 . Mechanistically, this treatment altered CD103 + dendritic cells, myeloid suppressors and T reg cells in the intestinal mucosa, resulting in suppression of antigen-specific T H 17 responses as well as increases in the levels of antimicrobial peptides and tight junction proteins.
Inflammation in at-risk populations
Several systemic immune abnormalities suggest the presence of ongoing mucosal inflammation in individuals at risk of developing RA (fig. 3) . One of these abnormalities is the predominance of IgA isotype ACPAs and RFs in retrospectively studied preclinical samples 58 as well as the presence of serum IgA ACPAs and RFs in at-risk populations 18 . More compelling, however, are data obtained from an analysis of plasmablasts from at-risk populations using new technologies 118 . During an immune response, peripheral blood plasmablasts arise from both naive and memory B cells that are activated by inciting antigens, including those at mucosal sites. To evaluate these cells, plasmablasts derived from RA-related autoantibody-positive at-risk individuals as well as matched controls and patients with early RA were sequenced and characterized utilizing a barcode-enabled single-cell antibody methodology 119 . Notably, although total plasmablast levels were similar in RA-related autoantibody-positive at-risk individuals and controls, a markedly increased frequency of IgApositive as compared with IgG-positive plasmablasts was observed in the at-risk individuals compared with the other groups 119 .
To analyse these cells in further detail, the researchers performed paired heavy-chain and light-chain repertoire sequencing on plasmablasts from a subgroup of at-risk patients and generated phylogenetic trees of paired IgG and IgA sequences [118] [119] [120] . From these data, clonal families of antibodies were identified that use www.nature.com/nrrheum the same heavy-chain V and J gene segments, as well as the same light-chain V and J gene segments, consistent with their interrelatedness during development. Combined IgG-IgA phylogenetic trees were also generated to demonstrate the relationship between sequences across these isotypes; remarkably, a substantial number of dual IgG-IgA cross-isotype clonal families of varying sizes were observed 119 . Because of the relationship between IgA responses and the mucosa as well as the isotype changes being present in plasmablasts, which are continuously being generated, these data are consistent with an ongoing immune response that has a pronounced mucosal origin and/or contribution. Other studies of at-risk individuals have also demonstrated findings consistent with a state of chronic immune stimulation and inflammation 121 , which, in the absence of another tissue or organ site of origin, is a finding consistent with mucosal inflammation. For example, in one study, peripheral blood cells from at-risk individuals exhibited unique phenotypes compared with that of control populations, which included increased levels of citrullinated histone H3 (citH3) as well as increased stimulated production of IL-2 and T H 17 cytokines but decreased T H 2 cytokine expression 121 . With regard to the underlying immune mechanisms of these particular findings, the abnormal features seem to be owing to the impaired induction of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in T cells. PTPN22 is a phosphatase that also suppresses citrullination independently of its phosphatase activity and when expressed as an RA-associated variant in neutrophils promotes accelerated NeTosis
.
In the same study of at-risk individuals, attenuated phosphatase activity of PTPN22 in T cells was found to result in aberrant expression of IL-2, ataxia telangiectasia mutated (ATM) and 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase 3 (PFKFB3), which is associated with a hyperproliferative phenotype 121 . Furthermore, diminished non-phosphatase activity of PTPN22 led to hypercitrullination mediated by peptidylarginine deiminases and reduction of expression of T H 2 cytokines. Notably, these T cell phenotypic changes identified in at-risk patients closely mirror results obtained in patients with longstanding RA -these studies showed that patients with active arthritis also exhibit pronounced changes in the metabolic activity of CD4 + T cells in which the cells do not metabolize glucose as efficiently as CD4 + T cells from healthy individuals, resulting in less intracellular ATP and increased sensitivity to apoptosis 123, 124 . Mechanistically, the defect was related to a lower induction of PFKFB3, with resultant metabolic shifts towards a hypoglycolytic phenotype in which the T cells divert glucose towards the pentose phosphate pathway, produce more NADPH (a reduced form of NADP) and consume more intracellular reactive oxygen species (ROS) 123 . In aggregate, these changes leave the T cells energy deprived, apoptosis sensitive and autophagy resistant. Subsequent studies demonstrated that insufficient activation of ATM (owing to ROS depletion) drove T cells towards a hyperinflammatory T H 17 and T H 1 lineage and enabled bypassing of the G2/M checkpoint and hyperproliferation 124 . Notably, correction of the ROS changes reversed these defects both in vitro and in an in vivo model 124 . Finally, one additional finding in support of the relevance of chronic immune activation at this early point in disease is the increased type I interferon score noted in individuals who subsequently transition from a late preclinical phase to classified RA 64 . In summary, several lines of evidence from peripheral blood and serum studies strongly suggest the presence of ongoing inflammation, probably mucosal in origin, in at-risk individuals and an immune response that is associated with a state of heightened immune reactivity. As the at-risk individuals do not show evidence of arthritis, as assessed by MRI, physical examination and even synovial biopsy, the presence of an asymptomatic chronic mucosal process associated with these peripheral blood changes is feasible.
Tissue-specific mucosal inflammation
Studies in at-risk populations that demonstrate the concurrent presence of inflammation and RA-related autoantibody production at various mucosal sites support the mucosal origins hypothesis in RA development. This section highlights available evidence regarding sitespecific changes in early RA as well as what is known in the same organ in at-risk populations.
Intestinal biomarkers. Seminal studies in patients
with new-onset RA demonstrated a relative expansion of faecal Prevotella copri in a substantial number of patients 13 . Although no microbiome-based replication studies have been published, findings in a separate study demonstrated an increased IgG and IgA humoral and T H 1 cell immune response to this organism in a subset of patients with established RA 125 . Another study of patients with established RA identified alterations in multiple strains of faecal and oral bacteria as compared with non-RA control individuals 15 , changes that partially normalized following drug treatment. In a separate cohort study, an expansion of rare bacterial species was found in patients with established RA; these species were suggested to be relevant because of their ability to modify experimental RA 16 . Notably, whether the changes at these sites in patients with active disease are causal or secondary to inflammation or drug therapy is unknown. In addition, it is unclear why the microbiome findings differ from one research group to another.
No comprehensive studies of the faecal or intestinal microbiome have been reported in populations at risk of RA. However, such studies are underway, and preliminary results suggest the presence of local ACPA production and dysbiosis in these individuals (K.A.K., K.D.D. and V.M.H., unpublished observations).
Lung biomarkers.
In addition to the risk factors described above, such as smoking, that have been largely identified in epidemiological studies of patients with RA, and the demonstration that ACPAs and RFs are produced in inducible bronchus-associated lymphoid tissue (iBALT) in patients with chronic RA 126 , compelling studies of early RA have supported the presence of substantial pulmonary inflammation in conjunction with arthritis. Findings from these studies include the presence of histological structural abnormalities as well as inflammation and ACPA production of a similar nature to that in the joint in lung biopsy samples and bronchoalveolar lavage fluid 127, 128 . Microbiome studies of the bronchoalveolar lavage of patients with early RA demonstrated that the microbiota was considerably less diverse and abundant than that in matched healthy controls and that the changes were quite similar to those in patients with sarcoidosis 12 . The dysbiosis could be attributed to the reduced presence of several genera and taxa. In addition, several clades correlated with the levels of autoantibodies both systemically and in the bronchoalveolar lavage, and the genus Pseudonocardia was the only taxa over-represented.
Whether these same dysbiotic changes are seen in atrisk individuals has not yet been reported. However, two techniques have assessed the presence of lung abnormalities and local RA-related autoantibody production in at-risk populations. First, high-resolution CT (HRCT) findings demonstrated the presence of small-airway abnormalities (bronchial wall thickening, bronchiectasis, bronchiolitis and air trapping) in the absence of arthritis in two-thirds of at-risk individuals, findings that were consistent with airway inflammation; joints were assessed and negative for inflammatory arthritis by both clinical examination and (in a subset of individuals) by MRI 129 . Notably, the presence of these small-airway abnormalities was not dependent on a history of current or prior smoking, which suggests that other aetiological factors must be involved. In addition, patients were not aware of any pulmonary problems and did not demonstrate evidence of lung abnormalities by pulmonary function testing.
The second technique utilized in at-risk populations has been induced sputum collection, a validated methodology that assesses changes in biomarkers derived from the small airways 17, 18 . This technique demonstrated the presence of IgA and IgG RA-related autoantibodies in the lung of at-risk individuals (which in this study comprised FDRs of patients with RA) even in the absence of serum ACPAs or RFs 18 . Analysis of the ratios of ACPA and RF levels to the total levels of mucosal IgA and IgG antibodies, and comparing those with the serum ratios of each, demonstrated that the RA-related autoantibodies were produced locally. Importantly, local IgA anti-CCP antibody generation was also closely associated with the concurrent presence of elevated levels of inflammatory cells (neutrophils and macrophages) and increased endogenous neutrophil extracellular trap (NET) formation in the sputum, as assessed by the detection and quantification of NET remnants 17 . In aggregate, ~25% of at-risk FDRs and individuals with serum autoantibody positivity seemed to demonstrate the presence of local RA-related autoantibody production. Furthermore, a subset of at-risk individuals demonstrated systemic ACPAs but no pulmonary inflammation, suggesting that a separate mucosal site is involved in those individuals in the generation of systemic ACPAs.
In addition, sputum studies comparing individual ACPA reactivities identified an increased number of sputum ACPA peptide reactivities in patients with RA compared with at-risk patients 130 . Although crosssectional, this finding suggests that epitope spreading, which is well described in the blood during the preclinical period leading to RA onset, also occurs at mucosal sites. Furthermore, in serum anti-CCP-positive patients with lung disease but no joint disease, lymphoid aggregates consistent with iBALT were highly prevalent, further supporting RA-related immune reactivity in the lung in at-risk individuals 131 .
Periodontal biomarkers. Periodontal inflammation, chronic periodontitis, P. gingivalis infection and antibody reactivity to citrullinated enolase have been associated with RA and RA severity (reviewed elsewhere 132 ). Although the relationship between RA and periodontitis has been challenged through population-based studies, such as studies of the EIRA cohort 133 , substantial data support a close relationship between the ACPA response, the specific P. gingivalis peptidyl arginine deiminase enzyme and RA risk.
Other factors implicated in linking RA to periodontitis and ACPA production include an elevated abundance of Anaeroglobus geminatus in the periodontal fluid in patients with new-onset RA that correlated with the presence of ACPAs and RFs and an increase in Prevotella and Leptotrichia species in patients with new-onset RA irrespective of the presence of periodontitis 14 . In another study, the presence of Aggregatibacter actinomycetemcomitans was associated with periodontitis in vivo, and this strain demonstrated the capacity for inducing hypercitrullination ex vivo in neutrophils 134 .
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In contrast to lung studies, understanding of the relationship between the RA at-risk state and periodontitis is more limited, as studies of that population are just being completed. Prior studies have demonstrated an increased prevalence of antibodies to P. gingivalis in at-risk populations 135 . In addition, initial metagenome sequencing reports from the periodontium of at-risk patients have begun to emerge, although no conclusions have been made available 136 . A study of patients with periodontitis without RA demonstrated the presence of citrullinated proteins as well as peptidyl arginine deiminase enzymes 2 and 4 in the periodontal fluid of a subset of patients; both of these components correlated with the level of inflammation and with ACPA levels in these patients 137 .
Nevertheless, no comprehensive studies of at-risk populations have been reported that can address the longitudinal relationships between local dysbiosis in the periodontium and the future development of RA. Thus, it remains uncertain whether, and in which direction, a causal relationship might exist in the at-risk and established RA populations.
Other mucosal site biomarkers: salivary, urinary and cervicovaginal. Comprehensive studies of other mucosal sites have not been reported in at-risk patients but are underway. In a small cohort of patients with RA, ~20% of individuals expressed increased salivary IgA ACPA levels relative to healthy individuals 138 . Notably, in that setting, IgA anti-CCP antibody positivity was found to be inversely associated with several poor patient outcomes, thus suggesting that the anti-inflammatory, protective functions of the IgA isotype described above are the predominant effect of expression at this site. To our knowledge, there are no similar studies of at-risk populations, although in a small set of samples there were marked differences between ACPA levels in induced sputum and saliva of at-risk patients 17 , suggesting that the two sites operate independently and consistent with the understanding that sputum ACPA levels reflect lung and not oral sources. Additional studies demonstrated that IgA RF was likely to be produced locally within the saliva and tears in patients with RA, but no studies of at-risk populations are available 139 . With regard to urinary biomarkers, it is uncertain whether urinary ACPAs are present in patients with RA or at-risk populations as this has not been studied to our knowledge. Urinary tract infections have been postulated to have a role in the development of RA, perhaps most notably infection with Proteus species (reviewed elsewhere 140 ), but no studies in at-risk populations have emerged that directly address this relationship. However, opportunities to study the urinary microbiome are increasing 141 . Finally, the cervicovaginal mucosal site has been evaluated with regard to the mucosal immune response and susceptibility to transmission of infections such as HIV 142 . Of interest, similar to findings discussed above demonstrating ACPAs in the sputum of individuals at risk of RA, antigen-specific antibodies for HIV can be found in cervicovaginal fluid in the absence of serum antibodies, consistent with a local-limited protective antibody response 143 . Although published studies of cervicovaginal-specific biomarkers and ACPA production are lacking, our group has identified increased levels of anti-CCP IgG antibodies in the cervicovaginal fluid of premenopausal women with RA as well as in some individuals in the at-risk state 144 . A portion of healthy controls in that study were also identified who were serum anti-CCP negative but had high levels of cervicovaginal fluid anti-CCP antibodies that strongly correlated with signs of local inflammation as measured by increased levels of cytokines. These findings further support the hypothesis that localized and externally focused ACPA production occurs at mucosal sites in response to inflammation and that identifying the mechanisms leading to a loss of externally focused ACPA production will improve our understanding of the development of systemic ACPAs in individuals who develop RA.
One limitation to the interpretation of the current studies, especially outside of the lungs, is a lack of understanding on a larger population basis of what the levels of mucosal ACPAs are, how these levels change over time and what additional phenotypes and factors are associated with antibody status. These questions are important areas for future investigation.
Potential disease mechanisms
Following initial phenotyping studies in populations at risk of RA and the demonstration of substantial systemic immune dysregulation, the study of local mucosal sites in at-risk individuals is now starting to accelerate. No comprehensive longitudinal studies of mucosal biomarkers have been reported yet. Nevertheless, the intersection of informative mechanistic studies in other settings with cross-sectional translational human studies in at-risk individuals provides a conceptual framework in which to consider the role of mucosal processes in preclinical RA.
Potential protective role of ACPAs. What is perhaps the most striking finding from initial work is that local mucosal production of IgA and IgG ACPAs and RFs is frequently present in at-risk individuals, ranging from 15-25% of individuals when evaluating a single isotype or autoantibody specificity in cross-sectional studies of the lung in at-risk populations to ~40% when considering all reactivities. In addition, local lung mucosal RA-related autoantibody production is not a fixed phenotype; preliminary studies suggest that individuals in the at-risk state both gain and lose anti-CCP antibodies over time (M.K.D. and K.D.D., unpublished observations).
With these observations and the knowledge gained from studies of the protective role of mucosal antibodies, the following hypotheses can be put forward (fig. 4) . First, local ACPA production does not reflect an inherent loss of tolerance to self-antigens but is rather a hard-wired form of natural IgA production, perhaps T cell-independent, in which ACPAs are normally externally directed into the mucosal fluid where they bind to citrullinated antigens that are released from neutrophils undergoing NETosis and macrophages that are present as part of a chronic inflammatory state in a mucosal site. Second, given that multiple mucosal sites have demonstrated the presence of local ACPA production, these findings suggest that RA does not have to begin in a single mucosal region but might instead originate in one of many sites that could vary from patient to patient. This finding could underlie the very heterogeneous manner in which the autoimmune process develops in the preclinical period, with neither specific ACPA peptide reactivities 9 nor individual or combinations of cytokines 10 being necessary or sufficient for the transition to classified RA. Third, it is likely that a major driver in early disease initiation is the loss of the mucosal barrier; thus, development of a systemic IgG ACPA response could reflect an unresolved state of inflammation in the mucosa. This process could be driven by dysbiosis, the nature of which might be similar from one individual to another, or alternatively might vary substantially across at-risk individuals or subsets thereof.
Going forward, to validate this hypothesis, a clear understanding of the relationships between systemic and mucosal B cells and the B cell receptor sequences that encode ACPAs must be generated through paired tissue and peripheral blood studies. These studies would evaluate whether the systemic and mucosal ACPA-producing and RF-producing B cells originate from the same clonal families, a finding that would link together their developmental pathways.
T cells and molecular mimicry as drivers of autoimmunity.
The strong association of RA with the SE implicates antigen presentation and CD4 + T cells in its pathogenesis. Studies have demonstrated that CD4 + T cells specific for joint-derived citrullinated peptides are present in increased numbers and with distinct phenotypes in RA 44, 45 . These cells probably have a role in the evolution of RA by both promoting tissue-specific inflammation and providing B cell help for the formation of high-avidity www.nature.com/nrrheum pathogenic ACPAs. Molecular mimicry has been proposed as one source of failed tolerance in RA and provides a framework with which to link the microbiome with genetic risk by identifying CD4 + T cells that respond to microbial and self-antigens that share similar motifs.
Several approaches are being used to address the molecular mimicry hypothesis. For example, motif analysis identified α-viral peptides with a similar motif to CII, a known autoantigen in RA 145 . A peptide sequence motif (DERAA) contained within HLADRB1*13, a protective allele in RA, has been shown to mediate thymic tolerance in the context of HLA-DQ, but when this molecule and the peptide derived from it are absent, the peptide sequence can be recognized by CD4 + T cells that are not tolerized during development and are thus cross-reactive with DERAA-containing microbially derived epitopes and the self-antigen vinculin 146 . This finding suggests a mechanism by which an initial failure of thymic tolerance is followed by activation with a microbial antigen that then supports a T cell and B cell response to citrullinated vinculin 146 . Proteomic tools (such as mass spectroscopy) have also been used to characterize RA-related epitopes through the elution of peptides from HLA class II molecules found in the synovium of patients with RA. This approach has identified novel autoantigens that are cross-reactive with microbial proteins and for which the corresponding T cell and B cell responses are increased in patients with RA 125 . As we increase our understanding of the microbial species that participate in the development of RA and determine which autoantigens are early targets of the immune response, the role of molecular mimicry in the development of RA should be further clarified.
Molecular mimicry and the hard-wired IgA response to citrullinated products of inflammation might both be necessary to develop classified RA. To address this question, regardless of whether the local mucosal ACPA immune response is meant to primarily react with citrullinated products of dead cells, the potential for molecular mimicry as a driver of an expanded pathogenic mucosal and then ACPA immune response, as recently demonstrated in type 1 diabetes 147 , should be further evaluated. Similarly, B cell molecular mimicry is consistent with plasmablast studies in patients with chronic RA, from whom IgG antibodies have been cloned and expressed and found to recognize citrullinated targets as well as P. gingivalis 148 . Notably, in patients with early RA, IgA ACPAs are associated with smoking whereas IgG ACPAs are associated with the SE, supporting a possible distinction between local and systemic processes 149 .
To better understand these causal mechanisms, and using a rationale similar to that used for ACPA-reactive B cells, characterizing citrullinated-peptide-reactive systemic and mucosal T cells and their interrelationships is essential to further evaluate the potential role of autoreactive T cells in the initial and subsequent development of ACPAs and then classified RA.
Other potential interrelated mechanisms. Other interrelated mechanisms might exist, including mechanisms that modify local ACPA generation and mechanisms by which ACPAs originating at different mucosal sites, or through distinct inflammatory processes, might influence the subsequent arthritis phenotypes. For instance, alternative primary drivers of autoimmunity might have key roles, such as inadequate local T cell immuno regulation influenced by genetic or environmental factors, aberrant expression of adhesion molecules and/or cytokines and chemokines, activation of non-tolerogenic antigen-presenting cells or engagement of non-traditional antigen-presenting cells such as fibroblasts. Additional modulators of the loss of tolerance and the autoimmune disease process might include metabolomic changes that promote systemic spread of the ACPA response, a physical or physiological break in the mucosal barrier, direct or indirect activation of transiting autoimmune cells through enhancement of antigen presentation or alteration of dendritic cell function to expand a response and production of innate immune factors that promote activation, such as lipopolysaccharide, high mobility group protein B1 (HMGB1), CpG or other danger-recognition molecules. In addition, acute infection in the presence of chronic local ACPA production might have an important role in triggering additional pathogenic changes.
An important question in the evolution of RA is how does chronic inflammation relate mechanistically to epidemiological factors such as smoking or low intake of omega-3 PUFAs? Studies suggest that smoking is associated with increased levels of citrullinated proteins in the lung 150 . With regard to the omega-3 PUFA levels and exposures, studies have shown that molecules derived from this pathway (especially bioactive lipid mediators including resolvins and maresins that are biosynthesized in vivo from EPA and DHA) are key factors in resolving or reducing inflammation 151 . The observation that RBC levels of omega-3 PUFAs are lower in those patients who progress to inflammatory arthritis suggests that these factors are either present in insufficient quantities or are consumed as part of the excessive mucosal inflammation that is present and that these two processes, local inflammation and a lack of appropriate levels of omega-3 PUFAs, are both necessary for continued evolution of disease. These anti-inflammatory compounds from the omega-3 PUFA pathway decrease inflammation through mechanisms including blocking neutrophil and other cell chemotaxis or recruitment, increasing neutrophil apoptosis and promoting cellular immune switching to regulatory phenotypes (reviewed elsewhere 83 ). Furthermore, the actions of agents such as resolvins have been shown to reduce inflammation at mucosal surfaces in the lung as well as elsewhere (for example, the gut) 152, 153 and to reduce cell activation and immune-complex-mediated inflammation in a variety of diseases, including IgA nephropathy 83, 154, 155 . Importantly, as described above, all of these pro-inflammatory pathways might be critical to the initiation and propagation of autoimmunity and the ultimate development of arthritis and thus might be modifiable by increasing intake of omega-3 PUFA levels.
As to the potential influence of mucosal inflammation at specific sites on subsequent arthritis generation, distinct synovial subtypes have been identified in RA, including subsets of patients with lymphoid-predominant or myeloid-predominant
Molecular mimicry
The development of autoreactivity commonly considered to be through the recognition of a microbial or other foreign pathogen peptide that is structurally similar to self-antigen.
synovial infiltrates versus patients with fibrous or lowinflammation synovial features 156 . The different synovial phenotypes in RA might correlate with different responses to biological therapeutics 156 . The specific mucosal trigger and IgA plasmablast response, either in general or from specific mucosal sites, might promote a transition to the high-grade synovial inflammatory subtype of RA, whereas other mechanisms might promote transition to the fibrous synovial subtype. It is also striking that what are two distinct autoantibody systems, ACPAs and RFs, can come together and accelerate and amplify joint damage in an experimental model of RA 157 , again highlighting the possibility that separate mucosal processes drive distinct autoantibody phenotypes and the interconnectedness of the responses drives arthritis.
Therapeutic implications
Although the exact roles of mucosal inflammation in the development of RA are still uncertain, current findings provide an impetus to consider specific mechanism-based therapeutic approaches that follow up on the findings of chronic immune activation and mucosal inflammation in at-risk individuals. For example, although omega-3 PUFA supplementation has not yet been formally tested in a clinical trial in preclinical RA, studies in animals and trials in humans across a range of diseases (including classified RA) have demonstrated that supplementation improves clinical parameters 82, 83 , strongly suggesting that supplementation can result in biological changes affecting the inflammatory process at multiple sites, including the mucosa, and might be able to prevent or delay the development of clinically apparent RA. Furthermore, although targeting IL-17 is not consistently beneficial in patients with established RA (reviewed elsewhere 158 ), findings in an at-risk population described above 121 , along with the known role of IL-17 in promoting mucosal inflammation 159 , suggest that therapeutic approaches directed at IL-17, or targeting T H 17 cells through IL-12-IL-23, might be particularly effective in preclinical RA. T H 17 cells might contribute to the evolution of preclinical RA via pathways and mediators other than IL-17, including IL-6, IL-21, IL-22 and TNF 160 , suggesting that these molecules are also therapeutic targets in preclinical RA. Other pathways that have roles in epitope spreading following the breaking of tolerance, including B7/CD28 and CD40:CD40L, should also be considered. The success of co-stimulatory pathway modulation in cancer immunotherapy highlights the importance of these pathways in regulating T cell responses, and we anticipate the involvement of other T cell pathways in the development of autoimmunity 161 . If so, therapeutically targeting these pathways in preclinical RA could provide a powerful approach to abrogate the development of RA. Of course, if a specific microbial species or metabolomic signalling pathway 162 is identified as causal in preclinical RA, targeting these processes would be especially effective.
Future directions
To test the hypotheses laid out above, a number of studies and experimental approaches must continue to be pursued. Longitudinal studies of the microbiome, local mucosal phenotypes at multiple sites and systemic RA-related autoantibody production are needed to determine whether potential causal relationships exist that could drive relevant phenotypic changes in the preclinical to clinical transitions. In a related fashion, understanding the causes of local mucosal inflammation and local ACPA generation should be a research goal. Additionally, exploring the relationships between local and systemic IgA and IgG ACPA production at the molecular and immunoglobulin sequence level over time will enable understanding of how these two systems are interrelated.
Although it is firmly established that local inflammation in the lung is associated with ACPA production, it is uncertain yet whether biomarkers of mucosal inflammation (such as faecal calprotectin) or responses to bacteria (such as increased expression of RegIII proteins) are altered in at-risk individuals. Beyond these considerations, although studies of single mucosal sites have been performed in at-risk individuals, a more comprehensive approach to simultaneously sampling multiple mucosal sites would reveal whether changes are unique to one site or are shared across multiple sites and then whether one site is sufficient to lead to systemic spread of ACPA generation. To address interrelationships between local mucosal findings and systemic immune changes, additional studies of T cell antigen-specific or innate immune reactivity should be evaluated, both systemically and at mucosal sites.
To further expand our understanding, a determination of whether other RA-related autoantibodies, including other AMPAs, are similarly generated locally in the mucosa as part of the hard-wired innate immune system and then spread systemically should be undertaken. Likewise, understanding how systemic immune and metabolomic changes relate to mucosal inflammation and ACPA production will provide additional insights. Finally, it will be important to determine whether this concept of 'hard-wired mucosal autoimmunity' having an important role in normal mucosal immune responses is relevant to the initial preclinical stages of other autoimmune diseases, such as systemic lupus erythematosus, in which antibodies to intracellular proteins are prominent. It is uncertain why these intracellular antigens that are released during normal inflammatory processes are 'chosen' as targets of autoantibodies in these conditions, and if these antibodies are expressed locally in a manner similar to RA at-risk individuals, unresolved mucosal inflammation might play a key early role in systemic spread.
Conclusions
Prior to the onset of the first clinical signs and symptoms of seropositive RA, most patients will have passed through a prolonged period of serological RA-related autoantibody positivity. Herein, we have reviewed the current understanding of the relationships during this preclinical period between mucosal alterations, including dysbiosis and inflammation, and the initiation of local and systemic ACPA production. Mucosal ACPA production in the lung, and probably other sites, is associated with the presence of local inflammation and increased levels of NET formation. Mucosal IgA ACPA production seems to be a hard-wired and www.nature.com/nrrheum common phenotype, suggesting that this factor has an important role in the local protective immune response outside of its eventual causal relationship with inflammatory arthritis. Many potential factors in the mucosa, as well as systemic alterations, could influence both the local initiation and systemic expansion of ACPA expression. Further study of these processes should provide both additional insights into very early disease pathogenesis in RA and the identification of novel therapeutic strategies.
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